VYD2311 Shift From IV to IM Could Widen Access: Michael Mina, MD, PhD

Captions are auto-generated.

VYD2311, Invivyd’s investigational next-generation monoclonal antibody designed to prevent COVID-19, demonstrated superior safety and tolerability when compared with an mRNA-based COVID-19 vaccine.¹

The phase 3 LIBERTY trial data (NCT07655180) position VYD2311 as a unique option that could increase access to COVID-19 prevention. VYD2311 shares the same antibody backbone as Invivyd’s other pre-exposure prophylaxis (PrEP) option, pemivibart (Pemgarda), which is only available under emergency use authorization for certain patients who are immunocompromised.¹ The company made very minimal changes when moving from pemivibart to VYD2311, altering “just a few amino acids,” said Michael Mina, MD, PhD, chief medical officer at Invivyd.

“[Those changes] actually increased the potency of the antibody about tenfold, if not more, which allows us to actually move from an IV administration to a single, simple injection into the arm as an intramuscular injection,” he explained in an interview with The American Journal of Managed Care^®.

This small change could make a substantial difference in administration and access for patients looking to stay protected against COVID-19. In LIBERTY, VYD2311 was administered as a 250 mg intramuscular (IM) injection, whereas pemivibart is a 4500 mg dose administered intravenously.¹

“Being able to provide somebody with a simple IM injection that doesn't appear to cause many adverse symptoms, in terms of injection site reactions or anything like that, we think is going to really change the game in terms of how many people can access this medicine and how easily they can get it,” Mina said.

Rather than traveling to an infusion site, patients could get the shot at a pharmacy or clinic, Mina said. As Invivyd works to bring VYD2311 to market, he said these access points, which would resemble how people get vaccines today, could change not only the type of protection people get but also how they think about when and how to get it.

“And if we fast-forward even further into the future, we're contemplating things like subcutaneous injections. Maybe people can do it at home,” Mina said.

References

1. McCrear S. VYD2311 shows superior safety vs mRNA COVID-19 vaccine. AJMC. October 1, 2026. Accessed October 8, 2026. https://www.ajmc.com/view/vyd2311-shows-superior-safety-vs-mrna-covid-19-vaccine